Pharm/Biotech:US,Europe stocks rally after US presidential election
US and European pharm/biotech stocks rose yesterday after Donald Trump wonthe US presidential election, a result that should put Democrat drug policy on hold.
Investor sentiment toward Korea’s pharm/biotech sector should pick up, as: 1) itlacks exposure to the US, which may lean toward trade protectionism; and 2)uncertainties at home and overseas are dissipating.
The valuation of Korea’s pharm/biotech sector has returned to pre-rally levels. Ourtop picks are Green Cross and Celltrion.